TY - JOUR
T1 - Corrigendum
T2 - Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency (Frontiers in Cellular and Infection Microbiology, (2023), 13, (1190867), 10.3389/fcimb.2023.1190867)
AU - Pasternak, Alexander O.
AU - Rohr, Olivier
AU - van Lint, Carine
AU - Kula-Pacurar, Anna
N1 - Funding Information: AOP acknowledges funding from the Dutch Medical Research Council (ZonMw), grant no. 09120011910035. CVL and OR acknowledge funding from the Belgian National Fund for Scientific Research (F.R.S-FNRS, Belgium); the French INSERM agency “ANRS/Maladies infectieuses émergentes”; the “Télévie” program of the F.R.S.-FNRS; ViiV Healthcare; the “Fondation Roi Baudouin”; the Internationale Brachet Stiftung (IBS); the Walloon Region (“Fonds de Maturation”); The “Amis des Instituts Pasteur à Bruxelles”, asbl.; the University of Brussels (ULB - Action de Recherche Concertée (ARC) grant); the NEAT (European AIDS Treatment Network) program; the University of Brussels (Action de Recherche Concertée ULB grant); the Marie Skłodowska-Curie COFUND action; and the European Union’s Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015. CVL is “Directrice de Recherches” of the F.R.S-FNRS. The laboratory of CVL is part of the ULB-Cancer Research Centre (U-CRC) (Faculty of Medicine, ULB). AKP acknowledges funding from the National Science Centre, Poland (Sonata Bis Grant UMO2018/30/E/NZ1/00874). Publisher Copyright: Copyright © 2023 Pasternak, Rohr, Van Lint and Kula-Pacurar.
PY - 2023
Y1 - 2023
N2 - In the published article, there was an error in the Funding statement. The Funding section misses the funding agency for AKP. The correct Funding statement appears below. FUNDING AOP acknowledges funding from the Dutch Medical Research Council (ZonMw), grant no. 09120011910035. CVL and OR acknowledge funding from the Belgian National Fund for Scientific Research (F.R.S-FNRS, Belgium); the French INSERM agency “ANRS/Maladies infectieuses émergentes”; the “Télévie” program of the F.R.S.-FNRS; ViiV Healthcare; the “Fondation Roi Baudouin”; the Internationale Brachet Stiftung (IBS); the Walloon Region (“Fonds de Maturation”); The “Amis des Instituts Pasteur à Bruxelles”, asbl.; the University of Brussels (ULB - Action de Recherche Concertée (ARC) grant); the NEAT (European AIDS Treatment Network) program; the University of Brussels (Action de Recherche Concertée ULB grant); the Marie Skłodowska-Curie COFUND action; and the European Union’s Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015. CVL is “Directrice de Recherches” of the F.R.S-FNRS. The laboratory of CVL is part of the ULB-Cancer Research Centre (U-CRC) (Faculty of Medicine, ULB). AKP acknowledges funding from the National Science Centre, Poland (Sonata Bis Grant UMO2018/30/E/NZ1/00874). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
AB - In the published article, there was an error in the Funding statement. The Funding section misses the funding agency for AKP. The correct Funding statement appears below. FUNDING AOP acknowledges funding from the Dutch Medical Research Council (ZonMw), grant no. 09120011910035. CVL and OR acknowledge funding from the Belgian National Fund for Scientific Research (F.R.S-FNRS, Belgium); the French INSERM agency “ANRS/Maladies infectieuses émergentes”; the “Télévie” program of the F.R.S.-FNRS; ViiV Healthcare; the “Fondation Roi Baudouin”; the Internationale Brachet Stiftung (IBS); the Walloon Region (“Fonds de Maturation”); The “Amis des Instituts Pasteur à Bruxelles”, asbl.; the University of Brussels (ULB - Action de Recherche Concertée (ARC) grant); the NEAT (European AIDS Treatment Network) program; the University of Brussels (Action de Recherche Concertée ULB grant); the Marie Skłodowska-Curie COFUND action; and the European Union’s Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015. CVL is “Directrice de Recherches” of the F.R.S-FNRS. The laboratory of CVL is part of the ULB-Cancer Research Centre (U-CRC) (Faculty of Medicine, ULB). AKP acknowledges funding from the National Science Centre, Poland (Sonata Bis Grant UMO2018/30/E/NZ1/00874). The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
KW - HIV
KW - HIV latency
KW - HIV latency reversal
KW - HIV persistence
KW - HIV reservoir
UR - http://www.scopus.com/inward/record.url?scp=85159856739&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fcimb.2023.1213356
DO - https://doi.org/10.3389/fcimb.2023.1213356
M3 - Comment/Letter to the editor
C2 - 37249980
SN - 2235-2988
VL - 13
JO - Frontiers in cellular and infection microbiology
JF - Frontiers in cellular and infection microbiology
M1 - 1213356
ER -